Pfizer, BioNTech COVID vaccine gets CHMP recommendation for ‘full’ MA for all indications

0
6

Pfizer Inc. PFE, +0.20% and BioNTech SE BNTX, +1.12% said Friday that the Committee for Medicinal Products for Human Use (CHMP) for the European Medicines Agency (EMA) has recommended the companies’ COVID-19 vaccine Comirnaty be converted to standard, or “full,” Marketing Authorization (MA) from conditional MA for all indications and formulations. The companies said the European Commission (EC) will review the CHMP recommendation and is expected to make a decision “soon.” The vaccine has been granted MA by the EC to prevent COVID-19 in people aged 5 years and older, and the current conditional MA has been expanded to include a booster dose. Shares of Pfizer have declined 22.2% year to date through Thursday and BioNTech have dropped 44.1%, while the S&P 500 SPX, -0.72% has lost 18.2%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Work hard, play harder: Citigroup sent 27 lucky junior bankers to toil beside one of Spain’s finest beaches
Next articleBrett Arends’s ROI: This is what the Social Security crisis looks like

LEAVE A REPLY

Please enter your comment!
Please enter your name here